News

MyChesCo on MSN1h
Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia Gravis
HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...
The American Journal of Managed Care18h
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...
Pharmaceutical Technology on MSN2d
EC approves argenx’s efgartigimod alfa for CIDP treatment
"EC approves argenx’s efgartigimod alfa for CIDP treatment" was originally created and published by Pharmaceutical Technology ...
The American Journal of Managed Care5d
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis
Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...